Phase 1 Melanoma Trial, Recruiting NCT07076550 Sponsor: Alpha-9 Oncology USA Inc. Condition: Melanoma
Back to Melanoma

Phase 1 Melanoma Trial, Recruiting

NCT07076550
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to read, understand, and sign a consent form agreeing to take part in the study
  • A special scan (PET scan) using a specific tracer has shown uptake in at least one measurable area of your cancer
  • Your melanoma has been confirmed by a lab test and cannot be surgically removed or has spread to other parts of the body, and it has continued to grow or worsen despite standard treatment
  • You are well enough to carry out basic daily activities (confirm with trial site for exact fitness level required)
  • Your liver, kidneys, and other organs are working adequately, as shown by blood tests taken within 14 days before starting treatment
  • You have recovered from significant side effects of any previous cancer treatments
  • If you are a woman who could become pregnant, you must have a negative pregnancy test and use reliable contraception during treatment and for at least 6 months after your last dose; if you are a man whose partner could become pregnant, you must use reliable contraception during treatment and for at least 3 months after your last dose

Who may not be able to join:

  • You have previously been treated with radioactive substances used as therapy (not including radioactive tracers used for scans)
  • You have recently taken part in another clinical trial with an experimental treatment shortly before starting this trial (with some exceptions — confirm with trial site)
  • You are currently receiving any other cancer treatment
  • You have had major surgery within 4 weeks before starting the trial treatment
  • You have been diagnosed with another type of cancer within the past 2 years
  • You currently have a serious active infection
  • You have previously had a serious reaction to any ingredients in the trial treatment
  • You have other serious health conditions, such as significant heart or severe infectious disease problems
  • You have significant cancer spread to your brain or central nervous system
  • You are pregnant, breastfeeding, or unwilling to use adequate contraception
  • The trial doctors believe that any other aspect of your health or situation could put you at risk or prevent you from following the trial requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +61 300 131 548

Australian sites

Alfred Health, Melbourne, Victoria
+61390763129
Austin Health, Melbourne, Victoria
+61 3 9496 5000
Fiona Stanley Hospital, Murdoch, Western Australia
+61426824336
GenesisCare Murdoch, Murdoch, Western Australia
+610893661500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Alpha-9 Oncology USA Inc.
Registry
ClinicalTrials.gov
Start date
19 November 2025
Est. completion
1 January 2028

Where this trial is recruiting

🇦🇺 Australia

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Determine max tolerated dose and recommended Phase 2 Dose; Incidence of treatment-related adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov